- Home
- NAT vs DCTH Comparison
NAT vs DCTH Comparison
Compare NAT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAT
- DCTH
- Stock Information
- Founded
- NAT 1995
- DCTH 1988
- Country
- NAT Bermuda
- DCTH United States
- Employees
- NAT N/A
- DCTH N/A
- Industry
- NAT Marine Transportation
- DCTH Medical/Dental Instruments
- Sector
- NAT Consumer Discretionary
- DCTH Health Care
- Exchange
- NAT Nasdaq
- DCTH Nasdaq
- Market Cap
- NAT 571.7M
- DCTH 630.4M
- IPO Year
- NAT 1997
- DCTH N/A
- Fundamental
- Price
- NAT $2.76
- DCTH $13.85
- Analyst Decision
- NAT Hold
- DCTH Strong Buy
- Analyst Count
- NAT 2
- DCTH 4
- Target Price
- NAT $3.50
- DCTH $24.00
- AVG Volume (30 Days)
- NAT 2.7M
- DCTH 531.5K
- Earning Date
- NAT 07-01-2025
- DCTH 08-04-2025
- Dividend Yield
- NAT 10.54%
- DCTH N/A
- EPS Growth
- NAT N/A
- DCTH N/A
- EPS
- NAT 0.17
- DCTH N/A
- Revenue
- NAT $327,115,000.00
- DCTH $53,850,000.00
- Revenue This Year
- NAT N/A
- DCTH $155.42
- Revenue Next Year
- NAT $6.07
- DCTH $37.93
- P/E Ratio
- NAT $16.38
- DCTH N/A
- Revenue Growth
- NAT N/A
- DCTH 1068.87
- 52 Week Low
- NAT $2.13
- DCTH $7.17
- 52 Week High
- NAT $4.23
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- NAT 52.76
- DCTH 37.03
- Support Level
- NAT $2.67
- DCTH $15.72
- Resistance Level
- NAT $2.89
- DCTH $17.35
- Average True Range (ATR)
- NAT 0.09
- DCTH 0.74
- MACD
- NAT 0.00
- DCTH -0.40
- Stochastic Oscillator
- NAT 51.79
- DCTH 2.23
About NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.